Translational relevance
The benefit seen from the addition of bevacizumab to standard chemotherapy in the ICON7 trial was relatively modest in the overall population studied in terms of progression-free survival (1.5 months). When additional clinical factors were used to identify the population of patients at high risk of progression, the benefit specifically to this group increased to 3.6 months. Several biomarkers predictive of bevacizumab response have been reported in a number of different tumours, with promising preliminary results. This translational research study aligned to the ICON7 trial identified a biomarker signature which appears to assist in identifying patients with ovarian cancer most likely to benefit from bevacizumab treatment.
Introduction
Epithelial ovarian cancer (EOC) causes significant morbidity and mortality worldwide with an estimated 21,880 new cases and 13,850 attributable deaths in 2010 (1) . Standard treatment for many years has involved debulking surgery combined with systemic platinum-based chemotherapy (2) . However, despite EOC being very chemosensitive, most patients subsequently develop recurrent disease and die. Novel drug targets include vascular endothelial growth factor (VEGF), with progression of EOC commonly being VEGF-driven and increased VEGF expression is associated with more advanced disease, ascites and a worse overall prognosis (3, 4) . Preclinical and early clinical data supported the further investigation of bevacizumab, a monoclonal antibody to VEGF, in the treatment of EOC.
ICON7 was a two-arm phase III international randomised open-label trial of 1528 women
with high risk early-stage or advanced-stage EOC, comparing six cycles of standard chemotherapy (carboplatin and paclitaxel) to six cycles of chemotherapy plus the addition of concurrent and maintenance bevacizumab. Initial results demonstrated that bevacizumab improved progression-free survival (PFS), but although statistically significant, over the entire trial population the absolute PFS benefit was only 1.5 months (5) . These data, along with the results of a similar trial, GOG218 (6) , have led to bevacizumab being licensed in combination with carboplatin and paclitaxel in the first-line treatment of advanced EOC.
Subset analysis within ICON7 demonstrated increased benefit when the population was restricted to those patients at higher risk of disease progression (FIGO stage IV disease or FIGO stage III disease with >1cm residual disease after surgical debulking), with an increase in median PFS of 3.6 months and a trend towards increased overall survival (OS). Identifying novel biomarkers to select patients with EOC who will derive most benefit from bevacizumab is important, and is also required for patients with glioblastoma, colorectal, lung and renal cancer where bevacizumab is also licensed for use, as there are no predictive biomarkers in clinical use. Patients participating in ICON7 were asked to donate tissue and longitudinal blood samples for use in future translational research projects. The ICON7 sample bank, with rigorous sample collection, processing and storage and associated high quality clinical data, provides an excellent opportunity to identify potential EOC prognostic and predictive biomarkers, and to perform initial validation. The aim of this study was to utilise serum samples from the ICON7 sample bank to identify, and subsequently validate, candidate biomarkers relating to bevacizumab use in EOC.
Methods

Patients and Samples
ICON7 patient recruitment, trial design and outcomes have been published elsewhere (5) . 
Proteomic biomarker discovery by LC-MS/MS
Serum samples from 10 patients within the ICON7 experimental arm were selected for biomarker discovery, grouped as 5 responders (complete and partial response) and 5 nonresponders (stable or progressive disease) defined by RECIST and/or CA-125 after 6 cycles of treatment. Selection on this basis was used as PFS data were not available at that time.
Research. Table 1 ). Paired serum samples at time point 1 (baseline) and time point 4 (pre-cycle 2) from each of the selected patients were subjected to proteomic analysis by label-free MS and candidate biomarkers of response selected (Figure 1b ).
For each sample, 200 µL of serum was filtered through 0.22 µm Spin-X filters (Corning) and 150 µL then depleted of the 14 most-abundant proteins using a Multiple Affinity Removal (MARS) human 14 column (7), leaving an average of 7% of the total protein in the samples.
Samples were concentrated using 15 mL 10kDa MWCO filters (Millipore), desalted using 2 mL 7 kDa MWCO ZEBA spin-desalting columns (Thermo Scientific) and 150 µg protein was digested with trypsin using filter-aided sample preparation (FASP) (7, 8) .
Peptides (triplicate injections each of 2 µg) were separated by online reversed-phase capillary liquid chromatography (LC) and analyzed by electrospray tandem mass spectrometry (MS) using a Thermo Orbitrap Velos (9) . Data were searched against an International Protein Index (IPI 3.80) human protein sequence database with MaxQuant 1.1.1.36 software (10) and the Andromeda search engine (11) . The initial maximal mass tolerance for MS scan was set to 10 ppm, the fragment mass tolerance for MS/MS was set to 0.5 Th. The maximum protein and peptide false discovery rates were set to 0.01. Labelfree quantitation was performed with MaxQuant.
Results were subjected to initial exploratory data analysis using principal component analysis and hierarchical clustering considering the whole profile together to identify gross patterns and identify potential outliers. Each protein was then examined separately to identify differences in protein abundance between responders and non-responders at time Author Manuscript Published OnlineFirst on August 9, 2013; DOI: 10.1158/1078-0432.CCR-13-0489 points 1 and 4 (Mann-Whitney tests) and to identify differences between these time points (Wilcoxon signed-rank tests). False discovery rate was estimated by the q-value method.
Biomarker validation by immunoassay
The mass spectrometry results from the discovery analysis were confirmed by immunoassay. Validation and exploration of initial findings was undertaken using a cohort of 92 patients (627 longitudinal samples (Supplementary Table 2 ): validation cohort I), with further validation in an additional 115 patients (baseline samples only: validation cohort II).
Samples in validation cohort I were selected to ensure similar numbers in each of the patient treatment and outcome groups described (limited by available assessable patients in the non-responder groups). Validation cohort II consisted of all remaining baseline samples from the biobank. Validation cohorts included patients from both arms of the trial (to enable markers differing specifically in response to bevacizumab and not just chemotherapy to be distinguished; Figure 1b) , were independent of each other and the discovery set and were representative of the trial population (Table 1) . Patients in the validation cohorts were separated around the median PFS (18 and 16.8 months in validation cohort I and II respectively) into early and late progressors (includes non-progressors). This differed from the RECIST-based criteria used for selection of patients for biomarker discovery as at the later time of validation sample analysis, the ICON7 trial PFS data, which is more clinically relevant than response or non-response, had become available.
An ELISA for soluble FLT4 (VEGFR3) was developed (Supplementary Methods) using the human sVEGFR3 DuoSet (R&D Systems) but with a substituted standard due to validation issues. Soluble mesothelin-related peptides (sMRPs) were quantified using the FDAapproved MESOMARK ® assay (Fujirebio Diagnostics) and AGP and CA-125 concentrations were measured using routine clinical assays (Behring Nephelometric Analyser II, Siemens and Siemens ADVIA Centaur CA-125 II assay respectively) at the Leeds General Infirmary.
Research. 
Statistical analysis
Results were examined for predictive utility, either on the basis of baseline concentrations or patterns of longitudinal change of the proposed protein biomarkers. All analyses were performed according to REMARK criteria (12) . Associations between the 4 biomarkers under study were visualised using a correlogram based on simple linear regression and Spearman's rank correlation coefficient. Associations with demographic and clinical characteristics at baseline were investigated using Fisher's exact test for categorical variables and Spearman's rank correlation coefficient for continuous variables. Corrections for multiple testing were not applied due to the explorative nature of the study.
Estimates of intra-and inter-subject variation for each of the selected proteins was obtained using linear mixed effects models (13) considering biomarker concentrations from pretreatment time points 1 and 2. Longitudinal line and box plots were used to assess trends in biomarker concentration over time to inform salient non-parametric significance testing of differences between time points. A linear mixed effect model was also used to investigate the rate of change of FLT4 concentration over time in patients in the experimental arm.
PFS was calculated from the date of randomization to the date of disease progression or death, whichever occurred first. Patients who were alive without disease progression were censored as of the date of their last assessment, with a cut-off date of November 30 th 2010.
Cox proportional hazards (PH) models were used to estimate the association between biomarker concentrations and PFS, the Kaplan-Meier (KM) method used to estimate survival functions and the logrank test used to compare survival functions. Markers were considered initially as continuous variates and then as binary factors using cut-points derived by maximising Harrell's C-index (for visualisation of effects) in validation cohort I and subsequently by predictive index-defined cut points in the combined data. The predictive potential of markers was assessed using interaction terms for treatment arm and biomarker concentration in Cox PH models.
Research. An additive marker index with scale 0-4 was calculated from the individual markers. Further details of marker index construction are provided in Supplementary Methods. Briefly, the optimum cut-point in the index was identified using Cox PH models (by examining the likelihood ratio test (LRT) on the interaction term for treatment arm and each level of the index), with indices below cut-points considered as signature-negative and those above as signature-positive. Internal validation of the optimal model was performed using R=1000 bootstrap resamples to estimate the optimism in model predictive ability. PH assumptions were tested for each model using tests based on Schoenfeld residuals (14) . All analyses were initially carried out in validation cohort I and replicated in validation cohort II and the cohorts combined, with the exception of longitudinal analysis which was carried out only in validation cohort I. All statistical tests were two-sided and all analyses were undertaken in the R environment for statistical computing (15) .
Results
Biomarker discovery phase
Serum profiling of the discovery cohort identified a total of 352 proteins with at least two significant and one unique peptide in the total data set (www.proteomics.leeds.ac.uk). From these, 4 proteins were selected on the basis of differences between responders and nonresponders, either at time point 1 or longitudinally: mesothelin, FLT4/VEGFR3 and AGP1 and 2. In the discovery cohort, mesothelin did not differ at baseline between responders and non-responders, but decreased in both groups, and was not detected in responders at time point 4 (Supplementary Figure 1) . FLT4 was only detected in two responders and at time point 1 only. Both these proteins were identified by only 2 peptides and therefore differences were potentially due to under-sampling during analysis, but given their biological relevance they were investigated further. Subsequent ELISA measurements of serum samples from 
Biomarker validation cohorts and clinical characteristics/associations
Biomarker validation cohort characteristics
The 3 candidate biomarkers together with CA-125 were examined in a further 207 patients (n=92 and 115 in validation cohort I and II respectively) from both arms of the trial in relation to disease progression. Baseline clinical and pathological characteristics and outcomes in the cohorts were similar to those in the overall trial population (Table 1) 
Association of biomarkers with clinical characteristics
Examination of candidate biomarkers (Supplementary Figure 3) and clinical characteristics at baseline in validation cohort I (Table 2) showed an association between mesothelin and FLT4 and patients at high risk of progression (p=0.002 and p=0.043 respectively), with patients at higher risk of progression having higher concentrations. These associations were confirmed in validation cohort II (Supplementary Table 3 ) and the combined validation cohort (Supplementary Table 4 
Biomarker validation -cohort I
Longitudinal changes in biomarkers during treatment
The inclusion in the validation group of 61 patients who had two baseline samples (ranging from 0 to 32 days apart) allowed for an estimate of "normal" intra-patient variation, important when considering biomarker changes in individuals during treatment. Intra-individual coefficients of variation (CV%) were 22.6% for mesothelin, 14.6% for FLT4, 12.0% for AGP Figure 5b) .
Association between candidate biomarker concentrations at baseline and PFS
When using the 88 time point 1 samples for which analyte measurements were available, each of the candidate biomarkers and CA-125 showed evidence of prognostic potential upon univariate analysis in Cox PH models ( Similar results were observed when stratifying analysis by treatment arm (Table 3 , column 3-4) and adjusting for high risk of progression status with the exception of mesothelin in the standard arm. This evidence of independent prognostic potential for FLT4 and AGP warrants further investigation in a larger cohort and was also evident in KM survival functions for optimal cut-points in biomarker concentration (Supplementary Figure 6) . None of these models showed evidence of violating the proportional hazards assumption.
Predictive potential of individual biomarkers
All three candidate biomarkers and CA-125 showed evidence of prognostic potential (Table   3 ). However, to determine if a marker has predictive potential a contrasting effect in treatment arms must be identified (usually through a significant treatment/biomarker interaction term in a Cox PH model). Cox PH models with terms for marker concentration, treatment and the relevant interaction term gave non-significant Wald tests on the interaction term, indicating that individually the markers showed no evidence of predictive potential 
A predictive biomarker index to inform treatment decisions
A biomarker index was constructed as described and when Cox PH models with index, experimental arm and interaction terms were estimated for the dichotomized index at each potential cut-point (no patients had index=0, implying dichotomization around 1, 2 and 3) the optimum model had a significant interaction term (p=0.006, LRT; full model shown in Supplementary (Figure 3a) . In the signaturenegative group, patients responded better to the standard therapy (median PFS standard arm not attained, but >42 months; experimental arm 22.8 months; p=0.051, logrank test), whereas in the signature-positive group the median PFS for patients on the experimental arm was 4.1 months longer (median PFS standard arm 13. 
Biomarker validation -cohort II
Association between candidate biomarker concentrations at baseline and PFS
The univariate associations seen between candidate biomarkers and PFS observed in validation cohort I were confirmed in validation cohort II (Table 3 : validation cohort II, p≤0.05). Multivariable associations overall and in each trial arm also showed similar effects, but were not statistically significant (p>0.05).
Validating the biomarker index
The biomarker index was re-calculated using the 115 time point 1 samples in validation 
Author Manuscript Published OnlineFirst on August 9, 2013; DOI: 10.1158/1078-0432.CCR-13-0489 associations were again seen (Table 3 : combined data, p≤0.003). Upon multivariate analysis the candidate markers and CA-125 were independently prognostic overall and in each arm separately (p≤0.045), the exception being FLT4 in the experimental arm (p=0.183).
Further validation of biomarker index
The biomarker index was recalculated using time point 1 samples from the 207 patients from validation cohorts I and II combined, using the same methods and cut-points as described have prognostic value, unfortunately none were individually predictive of benefit from the addition of bevacizumab. However, combining these with CA-125 in a biomarker index, a clear predictive value was seen in validation cohort I with signature-positive patients shown to benefit from the addition of bevacizumab.
We performed additional validation of the biomarker index in a further independent cohort of ICON7 patients. Using an approximation based on the LRT for interaction (21) higher baseline mesothelin being associated with poorer outcome/response in the validation set was not apparent in the MS data.
Selection of candidate biomarkers for further validation included consideration of biological relevance. Mesothelin is over-expressed in EOC, involved in tumour progression (22, 23) and associated with chemoresistance and a poorer overall prognosis (24) . It has also been proposed as a potential biomarker for EOC identification (25, 26) , and in mesothelioma as a putative biomarker to monitor response to treatment (27) . Our association between baseline mesothelin and risk of EOC progression may relate to increased disease burden. Mesothelin is synthesised as a precursor and cleaved to form soluble megakaryocyte potentiating factor and membrane-bound mesothelin. The two peptides identified in the MS study were both in the mesothelin part of the molecule and are present in variants including the soluble forms.
The immunoassay used detects forms including variant 1, most frequently found in ascitic fluid due to shedding from EOC cells (28) , and variant 3. 
example platelet-derived growth factor and fibroblast growth factor) found none to be of predictive value in a study of 106 patients with chemotherapy-resistant EOC treated with single agent bevacizumab (50) .
Based on the results from ICON7 and GOG218, bevacizumab is the first targeted therapy to be licensed for use in the first line treatment of EOC, in combination with carboplatin and paclitaxel. Current clinical practice is variable, with some clinicians using it in all patients with advanced EOC, and others using it only in those clinically identified at high risk of progression. There is clearly still a need to identify biomarkers predictive of response to bevacizumab, to enable avoidance of potential toxicities in those least likely to benefit and also to maximise the cost effectiveness of this drug. Our study has identified a biomarker index which appears predictive of benefit from bevacizumab but further validation of clinical utility in a larger population, including assessment of the predictive ability of all possible biomarker combinations, is needed.
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